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Available online 27 February 2017The interplay between vitamin D and the growth hormone (GH)/insulin-like growth factor (IGF)-I system is very
complex and to date it is not fully understood. GH directly regulates renal 1 alpha-hydroxylase activity, although
the action of GH in modulating vitamin D metabolismmay also be IGF-I mediated. On the other hand, vitamin D
increases circulating IGF-I and the vitamin D deﬁciency should be normalized before measurement of IGF-I
concentrations to obtain reliable and unbiased IGF-I values. Indeed, linear growth after treatment of nutritional
vitamin D deﬁciency seems to be mediated through activation of the GH/IGF-I axis and it suggests an important
role of vitamin D as a link between the proliferating cartilage cells of the growth plate and GH/IGF-I secretion.
Vitamin D levels are commonly lower in patients with GH deﬁciency (GHD) than in controls, with a variable
prevalence of insufﬁciency or deﬁciency, and this condition may worsen the already known cardiovascular
and metabolic risk of GHD, although this ﬁnding is not common to all studies. In addition, data on the impact
of GH treatment on vitamin D levels in GHD patients are quite conﬂicting. Conversely, in active acromegaly, a
condition characterized by a chronic GH excess, both increased and decreased vitamin D levels have been
highlighted, and the interplay between vitamin D and the GH/IGF-I axis becomes even more complicated
when we consider the acromegaly treatment, both medical and surgical.
The current review summarizes the available data on vitamin D in the main disorders of the GH/IGF-I axis, pro-
viding an overview of the current state of the art.
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Vitamin D1. Introduction
The relationship between vitamin D and the growth hormone (GH)/
insulin-like growth factor (IGF)-I system is complex and to date it is not
univocally clariﬁed. Adequate vitamin D levels are necessary for calcium
homeostasis and mineralization of the skeleton and vitamin D deﬁcien-
cy may contribute to low bone mineral density both in children and in
adult patients. When vitamin D concentrations are inadequate, calcium
absorption from the gut is also inadequate and its concentrations begin
to decrease. As serum calcium levels fall, there is increased activity of
parathyroid hormone (PTH), which promotes calcium loss from the
bone to counteract the decline in serum calcium concentrations and
the clinical features, such as rachitic bone changes, become apparent.rmone treatment; GHD, growth
tory and Endocrine-Metabolic
ecialist Medicine (DIBIMIS),
mo, Italy.
.In GH disorders, from GH deﬁciency (GHD) to GH excess, skeletal
disorders are a common condition [1]. However, the role of vitamin D
in bone health has not always been evaluated in these conditions. It is
well known that GH, either directly or indirectly through IGF-I, stimu-
lates osteoblastogenesis and chondrogenesis. Low bone turnover and
decreased bone mineral density are frequently reported in childhood-
onset GHD, while in patients with adult-onset GHD the data are discor-
dant [2,3]. On the other hand,markers of bone formation and resorption
increase in patients with GH excess [4].
Acromegalic osteopathy is a complication of acromegaly character-
ized by increase in bone turnover, deterioration in bone architecture
and high risk of vertebral fractures. However, the pathogenesis of acro-
megalic osteopathy ismultifactorial and fracturesmay occur even in the
presence of normal bone mineral density [5]. In this context too, the
impact of vitamin D concentrations is not fully clariﬁed. In addition,
the impact of vitamin D on metabolic diseases and the relationships of
vitamin D with diabetes, insulin resistance and metabolic syndrome
are being increasingly investigated. Given that both GHD and acromeg-
aly are associatedwithmetabolic abnormalities and that both 25OH-D3
and IGF-I levels are associatedwith themetabolic syndrome [6], a role of
vitamin D deﬁciency in these conditions cannot be ruled out. The
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disorders of the GH/IGF-I axis, with the aim of clarifying the role of vita-
min D in these conditions and providing an overview of the current
state of the art.
2. Selection of studies for review
PubMed was searched for English-language studies evaluating the
vitamin D levels in patients with GHD or acromegaly and/or their
changes over time after speciﬁc treatment. The search terms used
were “growth hormone and vitamin D”, “growth hormone deﬁciency
and vitamin D” and “acromegaly and vitamin D”. The studies that
were included reported vitamin D levels as the primary or secondary
objective of the study from1978 to Jun 2016. From the totality of studies
found using the above-mentioned key terms, 18 studies fulﬁlled our
criteria for analysis in GHD patients (Table 1) and 18 studies fulﬁlled
our criteria for analysis in acromegalic patients (Table 2).
3. Growth hormone/IGF-I axis and vitamin D
The relationship between vitaminDmetabolism and theGH/IGF axis
is shown in the Fig. 1.
3.1. GH and vitamin D
In rats it has been demonstrated that GH can modulate the renal
metabolismof 25-hydroxy vitaminD (25OH-D3) and affect intestinal cal-
ciumabsorptionby stimulating the productionof 1,25-dihydroxy vitamin
D [1,25(OH)2-D3], the hormonally active vitamin Dmetabolite [7]. In hy-
pophysectomized rats, the renal conversion of 25OH-D3 to 1,25(OH)2-
D3 was markedly reduced compared with sham-operated rats, whileTable 1
Selected studies for analysis on GHD patients.
Reference Diagnosis No. of
patients
Parameter
evaluated
Vit D levels
(compared
Gertner et al., 1979 CGHD 9 25OH-D3 –
1,25(OH)2-D3 –
24,25(OH)2-D3 –
Chipman et al., 1980 CGHD 7 1,25(OH)2-D3 –
Burstein, 1983 CGHD 12 –
1,25(OH)2-D3 –
–
Binnerts, 1992 AGHD 8 25OH-D3 –
1,25(OH)2-D3
Saggese, 1993 CGHD 26 1,25(OH)2-D3 Reduced
25OH-D3 Normal
Valk, 1995 AGHD 6 1,25(OH)2-D3 –
Amato, 1996 AGHD 9 25OH-D3 Similar
Hansen, 1996 AGHD 29 1,25(OH)2-D3 –
Wei, 1997 CGHD 12 1,25(OH)2-D3 Similar
24,25(OH)2-D3
25OH-D3
Boot, 1997 CGHD 39 1,25(OH)2-D3 Similar
Bianda, 1998 AGHD 8 1,25(OH)2-D3 –
–
de Boer, 1998 AGHD 50 1,25(OH)2-D3 Similar
Ahmad, 2003 AGHD 16 25OH-D3 –
1,25(OH)2-D3 –
Hitz, 2006 AGHD 34 1,25(OH)2-D3 Similar in m
Reduced in
25OH-D3 Similar
Ciresi, 2014 CGHD 80 25OH-D3 Reduced:
Deﬁciency (
Insufﬁcienc
Savanelli, 2016 AGHD 41 25OH-D3 Reduced:
Deﬁciency (
Insufﬁcienc
Witkowska-Sędek 2016 CGHD 84 25OH-D3 Reduced
CGHD: Childhood-onset growth hormonedeﬁciency; AGHD:Adult-onset growth hormone deﬁc
(OH)2-D3: 24,25-dihydroxy vitamin D; SA: somatostatin analogs; GHT: GH treatment; IGF-I T:the renal conversion of 25OH-D3 to 24,25-dihydroxycholecalciferol
[24,25-(OH)2-D3] was markedly increased. Treatment of rats with GH
for 10 days resulted in a signiﬁcant increase in renal conversion of
25OH-D3 to 1,25(OH)2-D3 and a signiﬁcant decrease in conversion to
24,25(OH)2-D3 [8,9].
Studies evaluating the role of GH in vitamin Dmetabolism in healthy
subjects support this concept. In 1994 Ogle et al. demonstrated a signif-
icant stimulatory effect of GH treatment on 1,25(OH)2-D3 levels in 11
healthy short-statured children [10]. Further, Marcus et al. conﬁrmed
this effect in 16 healthy elderly adults. Indeed, while aging is associated
with a decline in serum 1,25(OH)2-D3 levels [11], the authors of this
study speculated about the role of GH as a potential agent for attenuating
or reversing the loss of muscle and bone in elderly people [12]. Similar
stimulatory effects were obtained when GH was administered for a
short-time. Brixen et al. showed a signiﬁcant increase in total vitamin
D in 20 normal male volunteers after just 7 days of treatment with a
pharmacological dosage of GH [13], and GH infusions in 7 normal
healthymale volunteers increased 1,25(OH)2-D3 levelswithin 36 h [14].
3.2. IGF-I and vitamin D
The mutual relationship between IGF-I and vitamin D has been well
clariﬁed by studies performed in vitro and in vivo, in both children and
adults. However, whether GH acts on bone metabolism and vitamin D
directly or indirectly via increased IGF-I synthesis remains unclear.
It is well demonstrated that IGF-I directly stimulates production of
1,25(OH)2-D3 by kidney cells in vitro, independently of GH [15].
Similarly, in healthy subjects GH seems to affect serum 1,25(OH)2-D3
independently of circulating PTH, and this effect appears to bemediated
by IGF-I. Therefore, one potential mechanism by which GH stimulates
increases in bone mass is via increases in IGF-I and consequently inat baseline
to controls or to normal values)
Duration of treatment
(months)
Vit D levels after
treatment
12 Unchanged
Unchanged
Unchanged
5–14 Decreased
7 days Increased
1 Unchanged
12 Unchanged
6 Unchanged
Increased
12 Increased
Unchanged
6 Unchanged
12 Unchanged
12 Unchanged
6 Increased
Reduced/unchanged
Unchanged
36 Increased
3 days (GHT) Increased
5 days (IGF-I T) Increased
– –
12 Increased
Increased
en – –
women
–
40%)
y (35%)
12 Increased
51%)
y (26.8%)
– –
– –
iency; 25OH-D3: 25-hydroxy vitaminD; 1,25(OH)2-D3: 1,25-dihydroxy vitaminD; 24,25-
IGF-I treatment.
Table 2
Selected studies for analysis on acromegalic patients.
Reference No. of
patients
Parameter
evaluated
Vit D levels at baseline
(compared to controls or to normal values)
Treatment Duration of treatment
(months)
Vit D levels after
treatment
Eskildsen., 1979 15 1,25(OH)2-D3 Increased 6 Reduced
24,25(OH)2-D3 Increased Bromocriptine Reduced
25OH-D3 reduced unchanged
Brown, 1980 14 1,25(OH)2-D3 Increased – – –
Ho, 1992 25 1,25(OH)2-D3 Normal SA (5 pt) 6 Unchanged
Surgery (2 pt) – Unchanged
Fiebrich, 2010 19 25OH-D3 – SA 18 Reduced
Shah, 2012 2 1,25(OH)2-D3 Increased Surgery (1 pt) – Reduced
Incomplete surgery (1 pt) – Unchanged
Takamoto., 1985 12 25OH-D3 Reduced Surgery – Unchanged
1,25(OH)2-D3 Increased Reduced
Parkinson, 2003 16 25OH-D3 – Pegvisomant – Unchanged
1,25(OH)2-D3 – – Reduced
White, 2006 10 1,25(OH)2-D3 Increased Surgery – Reduced
Lund, 1981 14 1,25(OH)2-D3 Increased Bromocriptine 6 Reduced
24,25(OH)2-D3 Increased Reduced
Fredstorp, 1993 16 1,25(OH)2-D3 – Octreotide 8–14 days Increased
32 months Unchanged
Vitamin D-binding protein – 8–14 days Unchanged
32 months Unchanged
Cappelli, 2004 35 25OH-D3 Normal Lanreotide 24 Unchanged
1,25(OH)2-D3 Normal Unchanged
Bijlsma, 1983 17 1,25(OH)2-D3 – Bromocriptine (12 pt)
or
Surgery (5 pt)
– Decreased
24,25(OH)2-D3 – – Increased
Ho, 1992 25 1,25(OH)2-D3 Normal SA (5 pt) 6 Unchanged
Surgery (2 pt) Unchanged
Lombardi, 2013 9 25OH-D3 reduced SA 6 Unchanged
Ajmal, 2014 125 25OH-D3 Normal SA 3 Unchanged
76 Unchanged
Halupczok-Żyła., 2015 55 25OH-D3 Reduced – – –
Altinova, 2016 total 25OH-D3 Normal
Vitamin D binding protein Increased – – –
free 25OH-D3 Reduced
Kamenicky, 2012 16 25OH-D3 – 6 Unchanged
1,25(OH)2-D3 – – Decreased
Bonadonna, 2005 36 25OH-D3 Reduced – – –
25OH-D3: 25-hydroxy vitamin D; 1,25(OH)2-D3: 1,25-dihydroxy vitamin D; 24,25-(OH)2-D3: 24,25-dihydroxy vitamin D; SA: somatostatin analogs.
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that IGF-I regulates 25OH-D3 concentration in 253 healthy adult males
[17]. Indeed, it is widely demonstrated that IGF-I causes an increase in
the circulating levels of 1,25(OH)2-D3 by directly stimulating expres-
sion and activity of the 1α-hydoxylase that produces 1,25(OH)2-D3 in
the kidney [14,18].3.3. Vitamin D and IGF-I
In epiphyseal chondrocytes, 1,25(OH)2-D3potentiates IGF-I synthesis
and stimulates cell differentiation and this proliferative effect ismediated
by local IGF-I synthesis [19]. In addition, it has been demonstrated that
mice knocked out for the vitamin D receptor (VDR) have lower IGF-I
levels compared with controls [20].
Soliman et al. measured the circulating 25OH-D3 and IGF-I in 46
children with vitamin D deﬁciency before and 6 months after treat-
ment with one intramuscular injection of vitamin D3 megadose
(300,000 IU). At presentation, patients were signiﬁcantly shorter
and had markedly lower growth velocity compared with normal
controls. Six months after treatment, height and growth velocity in-
creased signiﬁcantly in concomitant with a signiﬁcant increase in
25OH-D3 levels. The 25OH-D3 concentrations were signiﬁcantly
correlated with the IGF-I levels both before and after treatment,
and a signiﬁcant correlation was found between growth velocity
after vitamin D treatment and the increase in IGF-I and 25OH-D3
levels. These data denote that accelerated linear growth after treatment
of nutritional vitamin D deﬁciency ismediated through activation of theGH/IGF-I system and suggests an important role of vitamin D as a link
between the proliferating cartilage cells of the growth plate and GH/
IGF-I secretion [21]. These data have been conﬁrmed by Ameri et al.,
who prospectively measured IGF-I levels before and after 12 weeks of
treatment with oral vitamin D3 (5000 or 7000 IU/week) vs. no inter-
vention in 39 healthy adults. They found that in the 7000 IU group,
IGF-I levels signiﬁcantly increased, while they did not change in con-
trols. In addition, the concentration of 25OH-D3 was retrospectively
assessed in 69 GHD patients on stable hormone replacement. The
authors demonstrated higher IGF-I levels in GHD patients with higher
25OH-D3 levels (≥15 ng/ml), and a logistic regression analysis con-
ﬁrmed a signiﬁcant positive association between ≥15 ng/ml 25OH-D3
levels and higher IGF-I [22]. Conﬁrmatory data in healthy populations
were collected by Bogazzi et al., who identiﬁed a positive relationship
between serum 25OH-D3 and IGF-I concentrations in 241 healthy sub-
jects [23], and by Hippönen et al. in a large population of 6810 British
adult subjects [6], concluding that 25OH-D3 status may contribute to
determining serum IGF-I levels.4. GHD and vitamin D
It is well established that GHD is associated with decreased
bone mineral density in children and adults [24], in addition to a
series of cardiovascular risk factors. Although GH and IGF-I have
direct skeletal and metabolic effects, it is also possible that reduced
vitamin D levels may mediate some of the deleterious consequences
of GHD.
Fig. 1. Relationship between vitamin D metabolism and the GH/IGF axis. 25OH-D3: 25-hydroxy vitamin D; 1,25(OH)2-D3: 1,25-dihydroxy vitamin D; 24,25-(OH)2-D3: 24,25-dihydroxy
vitamin D.
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Several studies have investigated vitamin D status in patients, both
adults and children, with overt GHD, with discordant results.
In 1998 de Boer et al. showed reduced serum1,25(OH)2-D3 levels in
adult patients with childhood-onset multiple pituitary hormone deﬁ-
ciencies (MPHD), while these results have not been conﬁrmed in pa-
tients who had isolated GHD, probably as a result of a non-optimal
thyroid, gonadal, or adrenal hormone replacement. The ratio of
1,25(OH)2-D3 to 25OH-D3 was signiﬁcantly lower than normal only
in patients with MPHD, even when the ratio was adjusted for serum
PTH and, overall, 33% of the MPHD patients had 1,25(OH)2-D3 levels
below the 5th percentile. Because of these evidences, the authors did
not consider GHDas a condition of vitamin D deﬁciency [25]. Similar ev-
idences of normal vitamin D levels have been found by other authors in
studies performed in both childhood and adult-onset GHD [26–28].
Conversely, reduced 1,25(OH)2-D3 or 25OH-D3 levels in children
with GHD have also been demonstrated [29,30]. Ciresi et al. found that
40% of Sicilian children with GHD at baseline had vitamin D deﬁciency
and 35% had vitamin D insufﬁciency, respectively [31]. Similarly,
Savanelli et al. showed a prevalence of 51% of vitamin D deﬁciency
and 27% of vitamin D insufﬁciency in GHD adult patients [32]. By con-
trast, Hitz et al. showed a gender difference in vitamin D levels of
adult GHD patients at baseline. Indeed, 1,25(OH)2-D3 and the metabo-
lite 25OH-D3 of themale subjects were at the same level in patients and
healthy controls, while female patients had signiﬁcantly lower levels of
1,25(OH)2-D3 without any difference in 25OH-D3 levels [33].4.2. Impact of GH treatment on vitamin D levels
Vitamin D sufﬁciency may be required to obtain optimal effects of
GH treatment on bone quality in GHD patients. In a prospective study
conducted in 57 adult GHD patients treated with GH for 2 years, adifferential effect of GH treatment on bone mineral density was ob-
served, according to the vitamin D levels. Indeed, the trabecular bone
score only increased in the cohort of patients with 25OH-D3 above the
50th percentile [34].
However, only a few conﬂicting studies have prospectively analyzed
vitamin D before and after GH treatment and the reports on the effects
of GH treatment on vitamin D and its metabolites vary from a decrease
to no change or an increase after treatment.
Chipman et al. in 1980 have hypothesized a relative intestinal resis-
tance to vitaminD in childrenwithGHDbecause of the evidence of a de-
crease in serum 1,25(OH)2-D3 after 5–14months of GH treatment [35].
By contrast, some studies have shown no signiﬁcant effect of GH
treatment on vitamin D levels, in both children and adults. Changes in
vitamin D metabolites were studied in 9 children with GHD before
and duringGH treatment by Gertner et al. By comparisonwith pretreat-
ment values, the GH-treated children showed no signiﬁcant change in
serum concentrations of 25OH-D3, 1,25(OH)2-D3 and 24,25(OH)2-D3.
The authors concluded that although GH has been proposed as a regula-
tor of vitamin D metabolism, the results of this study demonstrate that
the changes in bone metabolism accompanying GH treatment are not
mediated via changes in vitamin D status [36]. In 12GHD children treat-
ed for 1 week with high dose (5 IU/day) GH therapy, and again at
1 month, 3 months, and 1 year of replacement therapy (0.1 IU/kg to a
maximum dose of 2 IU three times weekly), Burstein et al. found that
the mean serum 1,25(OH)2-D3 concentration signiﬁcantly rose on
the seventh day of high-dose therapy, returning to pre-therapy
values by 1month. The authors concluded that high dose GH therapy
in GHD children markedly raises the 1,25(OH)2-D3 concentration,
but that long-term, physiological replacement therapy does not produce
this effect [37].
In 1996 Amato et al. evaluated the effect of 12 months of GH treat-
ment in 9 adult patients with congenital (7 patients) and acquired (2
patients) GHD. Serum 25OH-D3 and other markers of bonemetabolism
were evaluated before, after 12 months of therapy and after 12 months
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Despite a signiﬁcant improvement in IGF-I levels and in bone mineral
density, no signiﬁcant changes were found during the study in vitamin
D and in other bone markers, indicating that GH acts on bone structure
and its effects can be direct or mediated by IGF-I and not by vitamin D
[28]. However, the low dose used and the frequency of GH administra-
tion must be taken into account in the interpretation of these results.
Similar results came from the study by Hansen et al., who showed
unaltered 1,25(OH)2-D3 levels in 29 adult patients with GHD treated
with GH for 12 months [38]. Similarly, 6 months of GH treatment did
not affect the 1,25(OH)2-D3 levels in a small group of GHD adults in
the study by Valk et al. [39].
Conversely, several studies found that GH administration had a stim-
ulatory effect on serum 1,25(OH)2-D3 and the mechanism seems to be
the enhanced activity of renal 1 alpha-hydroxylase through IGF-I. This
evidence could explain the correlation between the increase in vitamin
D, IGF-I and bone mineral density [40]. A few years ago the effect of GH
treatment on vitamin D metabolism was evaluated in 26 children with
GHD. All children showed a signiﬁcant increase in serum levels of
1,25(OH)2-D3 after 12 months of GH treatment [29]. The results of
the study by Wei et al. performed on 12 GHD children before and after
6months of GH treatment showed levels of vitaminDmetaboliteswith-
in normal ranges before treatment and conﬁrmed the action of GH in
modulating vitamin D metabolism mediated by IGF-I, and not PTH. In
that study, the authors demonstrated that 1,25(OH)2-D3 levels in-
creased after 1 and 3 months of treatment; 24,25(OH)2-D3 levels
were decreased at 1 and 3 months, and then returned to the baseline
levels at 6months, whereas 25OH-D3 levels did not signiﬁcantly change
[27]. A similar stimulatory effect of GH on 1,25(OH)2-D3 levels was
demonstrated by Boot et al. in 39 GHD children after 36 months of GH
treatment [26]. Ciresi et al. showed a low prevalence of vitamin D sufﬁ-
ciency (25%) in a cohort of 80 GHD children, with a signiﬁcant correla-
tion between vitamin D and the area under the curve of GH calculated
during the stimulation test at diagnosis. After 12 months of GH treat-
ment, a signiﬁcant increase in prevalence of children with vitamin D
sufﬁciency (50%) was found. The absence of correlation between vita-
min D and IGF-I levels in this study suggested a direct stimulatory effect
of GH on vitamin D, not necessarily mediated by the IGF-I increase. This
ﬁnding was supported by the evidence that children with lower GH
values, and not IGF-I, at baseline showed concomitant lower vitamin D
levels [31].
Comparable data have been reported in studies performed in adult
GHD patients. In 1992 Binnerts et al. demonstrated an increase in
1,25(OH)2-D3 levels, with unchanged 25OH-D3, after 6 months of
treatment in 8 adult patients [41]. Conversely, Ahmad et al. investigated
the effects of 1, 3, 6, and 12months of GH treatment in 16 adult patients,
showing a signiﬁcant increase in both 1,25(OH)2-D3 and 25OH-D3
levels [42]. In addition, Bianda et al. demonstrated that IGF-I stimulates
renal 1 alpha-hydroxylase activity in vivo. In 8 adult GHDpatients treat-
ed short-termwith continuous subcutaneous infusion of IGF-I and with
daily subcutaneous injection of GH in a randomized cross-over study,
the total 1,25(OH)2-D3 rose signiﬁcantly although the PTH, calcium,
and phosphate levels remained unchanged [43]. Therefore, IGF-I admin-
istration, similarly to GH, seems tobe able to stimulate bonemetabolism
and the production of 1,25(OH)2-D3 in GHD adults.
During the last few years, vitaminDdeﬁciency has also emerged as an
additional potential cardiovascular risk factor [44–46]. The impact of
vitamin D deﬁciency on cardiovascular risk was explored by Savanelli et
al. in 41 hypopituitaric patients with GHD and 41 controls. The authors
showed an association between the presence of hypovitaminosis D and
the prevalence of dyslipidemia, hypertension and metabolic syndrome
and stated that hypovitaminosis D was the most powerful predictor of
the prevalence of dyslipidemia and hypertension, suggesting the involve-
ment of vitamin D in the cardiovascular risk in GHD patients [32]. There-
fore, its metabolic role in GHD has generated growing interest [47]. It is
noteworthy that the interplay between vitamin D and GH/IGF-I systemmay be even more complex than it appears because of local interactions
in vessels. Indeed, the role of vitamin D in the relationship between
carotid artery intima-media thickness and IGF-I levels has been hypothe-
sized [48].
4.3. Summary
The majority of authors evaluating vitamin D in GHD showed
decreased levels in GHD patients, with a gender difference found only
in 1 study, while in 4 studies GHD was not considered a condition of
vitamin D deﬁciency. If vitamin D sufﬁciency seems to be required to
obtain optimal effects of GH treatment, the impact of GH treatment on
vitamin D levels remains controversial. While in just 1 study performed
in children vitamin D levels decreased during GH therapy, the majority
of studies have shown unchanged or increased vitamin D levels. Specif-
ically, 2 studies performed in children and 3 studies performed in adults
showed no effect of GH on vitamin D, while 4 studies in children and 3
studies in adults conﬁrmed a stimulatory effect of GH. Conversely, very
few studies have evaluated vitamin D deﬁciency as a cardiovascular risk
factor in GHD.
5. Acromegaly and vitamin D
In acromegaly, a condition characterized by chronic GH excess, both
increased anddecreased vitaminD levels have been highlighted and the
interplay between vitamin D and GH/IGF-I axis becomes even more
complicated when we consider acromegaly treatment, both medical
and surgical.
5.1. Impact of acromegaly on vitamin D levels
In 1979 Eskildsen et al. performed one of the ﬁrst studies on vitamin
D metabolism in acromegaly. In 15 acromegalic subjects the authors
found elevated plasma levels of both 1,25(OH)2-D3 and 24,25(OH)2-
D3. SerumPTH being normal in all patients, without measurable chang-
es during the observation period, the high basal vitamin D levels might
therefore be explained by a direct effect of GH rather than by increased
PTH action. Conversely, 25OH-D3 was low at baseline [49]. The authors
postulated that the low serum 25OH-D3 concentrations found in acro-
megalic patients might be due to a direct effect on the liver microsomal
enzyme system, since it is well known that GH decreases the hepatic
microsomal metabolism of a number of drugs [50]. Similar data about
increased circulating 1,25(OH)2-D3 concentrations in acromegaly
have been found by other authors. For example, in 1980 Brown et al.
showed high 1,25(OH)2-D3 levels in 14 acromegalic patients,
conﬁrming that GH is an important regulator of renal vitamin Dmetab-
olism [51].
Case reports documented 2 cases of 1,25(OH)2-D3-dependent hy-
percalcemia associated with GH excess. In these cases, the complete re-
section of the pituitary tumor produced biochemical remission of
acromegaly and normalization of calcium and 1,25(OH)2-D3levels,
while incomplete resection was associated with persistent 1,25(OH)2-
D3-dependent hypercalcemia. In these patients, acromegaly was con-
sidered a cause of 1,25(OH)2-D3-dependent hypercalcemia [52].
Regarding the relationship between total vitamin D concentrations
and acromegaly, in 1985 Takamoto et al. studied a small group of pa-
tients with acromegaly, showing that the mean serum 25OH-D3 levels
were signiﬁcantly lower and the 1,25(OH)2-D3 levelswere signiﬁcantly
higher in acromegaly compared with normal subjects. The authors con-
cluded that excessive GH secretion might stimulate production of
1,25(OH)2-D3 and might also directly stimulate calcium absorption
[53]. Similarly, other studies have conﬁrmed the higher levels of 1,25
(OH)2-D3 in acromegalic patients when compared to normal healthy
controls [54]. In addition, Lund et al. demonstrated that acromegalic
subjects have elevated serum levels of both 1,25 (OH)2-D3 and 24,25
(OH)2-D3, perhaps as a consequence of a direct action of GH on renal
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with active and inactive acromegaly and observed similar 25OH-D3
and increased 1,25(OH)2-D3 levels in active acromegaly [56]. The
mechanism of the increase in serum 1,25(OH)2-D3 in acromegaly
may involve a pathway independent from the PTH-mediated pathway,
as documented by a case report presented by Ueda et al., which report-
ed a case of primary hyperparathyroidism associated with acromegaly.
Although serum PTH levels increased after resection of the pituitary ad-
enoma, levels of serum 1,25(OH)2-D3 remained above the normal
upper limit. In addition, since serum 1,25(OH)2-D3 levels decreased in
spite of the increase in serum PTH levels after normalization of GH
levels, GH may have contributed to the elevation of serum 1,25(OH)2-
D3 [57]. In addition, it has been postulated that patients with acromeg-
aly have larger skin areas, which potentially could result in increased
25OH-D3 synthesis and increased 1,25(OH)2-D3 production [58].
Conversely, some studies have not shown any alteration in vitamin
D levels in acromegaly. In a study performed on 126 patients with
acromegaly, mean vitamin D levels were sufﬁcient at baseline [59].
These data were conﬁrmed by Ho et al., who showed 1,25(OH)2-D3
levels within normal limits in a case series of 25 acromegalic patients
[60]. The normal 1,25(OH)2-D3 levels in this group could suggest
the mechanism of increased gut sensitivity to 1,25(OH)2-D3 in these
patients [61].
On the other hand, few studies have shown low vitamin D levels in
acromegalic patients. In 55 acromegalic patients, divided into those
with active acromegaly (AA), well-controlled acromegaly (WCA) and
cured acromegaly (CA), Halupczok-Żyła et al. recorded vitamin D deﬁ-
ciency in all AA patients (100%), 13 WCA patients (92.86%), and 10 CA
patients (62.5%), concluding that active acromegalic patients have
lower vitamin D levels in comparison with controls and are at higher
risk of vitamin D deﬁciency. The authors indicated that this result may
be related to the higher BMI in the active acromegaly [62]. Similarly,
Bonadonna et al. found low total 25OH-D3 levels in postmenopausal
women with acromegaly who had vertebral fracture compared to
women with acromegaly who had no vertebral fracture [63].
There are no data about free 25OH-D3 concentrations, which are
suggested to be important in the determination of vitamin D deﬁciency,
in acromegaly. Altinova et al. studied 54 patients with acromegaly and
32 control subjects who were similar according to age, gender, and
body mass index. In this setting the authors for the ﬁrst time evaluated
free 25OH-D3 levels, in addition to the vitamin D binding protein
(VDBP). Serum VDBP levels were found to be increased in patients
with acromegaly compared to control subjects, while there was statisti-
cally no signiﬁcant difference in serum total 25OH-D3 levels. Converse-
ly, the authors found lower free 25OH-D3 levels in patients with
acromegaly compared to control subjects. Although the role of excess
GH and IGF-I in the regulation of VDBP is not currently known, as a hy-
pothesis, the IGF-I excess in patients with acromegaly may have some
effects on VDBP concentrations via paracrine mechanisms since both
IGF-I and VDBP are secreted from the liver [64].
In 52 acromegaly patients VDR polymorphism was hypothesized to
play a role in the course of acromegaly as a consequence of altering
hormonal status. Consequently, the authors stated that vitamin D levels
should be considered and followed up in the treatment of acromegaly
patients [65].
5.2. Impact of acromegaly treatment on vitamin D levels
Acromegaly treatment, both medical and surgical, seems to signiﬁ-
cantly impact on vitamin D levels in themajority of the studies, although
not all studies are in agreement on this.
Medical treatment with bromocriptine for 6 months was found to
signiﬁcantly reduce the plasma levels of both 1,25(OH)2-D3 and
24,25(OH)2-D3. Conversely, 25OH-D3 remained unaffected by the treat-
ment [49]. Similar data were found by Lund et al., who demonstrated a
signiﬁcant decrease in serum concentrations of 1,25 (OH)2-D3 and24,25 (OH)2-D3 accompanied by a reduction in urinary GH excretion
after a period of about 6 months of bromocriptine treatment [55]. The
impact of bromocriptine on vitamin D levels was also evaluated by
Bijlsma et al. in 17 acromegalic patients, who responded to either med-
ical treatment with bromocriptine (12 patients) or transsphenoidal sur-
gery (5 patients). Serum 1,25(OH)2-D3 decreased and 24,25(OH)2-D3
increased,without a correlation between the changes in serumGH levels
and 1,25(OH)2-D3, suggesting an indirect effect of growth hormone on
renal 1 alpha-hydroxylase [66].
Given that somatostatin analogs (SA) can increase fat in the
stools, which can lead to loss of fat-soluble vitamins, the prevalence
of fat-soluble vitamin deﬁciencies in long-term SA users was investi-
gated in 19 acromegalic patients using SA for ≥18 months. Deﬁciency
for 25OH-D3 occurred in 21% of the patients and treatment duration
did not inﬂuence vitamin levels. The authors concluded that fat-soluble
vitamin deﬁciencies are frequent during long-term SA treatment
and that these vitamins, including vitamin D, should be monitored in
these patients [67].
Conversely, some studies did not show any alteration in vitamin D
levels during medical treatment. In a study performed on 126 patients,
25OH-D3 levels were evaluated longitudinally prior to and during short
(mean 3 months) and long-term (mean 49months) SA administration.
Mean 25OH-D3 levels did not change during short and long-term SA
therapy, suggesting that long-term SA therapy does not affect serum
vitamin D [59]. Similar data were found by Cappelli et al., who demon-
strated that 24 months of treatment with lanreotide in 35 patients with
acromegaly did not associate with signiﬁcant changes in 1,25(OH)2-D3
levels [68]. Conversely, only during the short-term treatment (8 and
14 days) with octreotide, was a rise shown in mean serum 1,25(OH)2-
D3, with no changes in VDBP [69]. Ho et al. also evaluated the effect of
SA and surgical treatment in 5 and 2 patients respectively, showing
that serum 1,25(OH)2-D3 did not change after both treatments [60].
Sixteen patients with acromegaly treated with the growth hormone
receptor antagonist, pegvisomant, had a reduction in 1,25(OH)2-D3
levels after normalization of IGF-I, with unaffected 25OH-D3 levels.
These data provided further evidence of the effectiveness of pegvisomant
in normalizing the altered biological effects of GH hypersecretion [70].
As regards the impact of surgical therapy, Takamoto et al. in 1985 stud-
ied a small group of patients with acromegaly before and 3–4weeks after
pituitary adenomectomy. The serum 25OH-D3 levels did not change,
while the serum 1,25(OH)2-D3 concentrations fell signiﬁcantly [53].
Similarly, White et al. demonstrated a reduction in 1,25(OH)2-D3 levels
in 10 patients after surgical treatment of acromegaly [54].
5.3. Summary
The majority of studies showed increased vitamin D levels in
acromegalic patients, conﬁrming that GH is an important regulator of
renal vitamin D metabolism, likely due to a direct action of GH on
renal 1 alpha-hydroxylase activity. Similarly, almost all studies agree
in showing a decrease in vitaminDduringmedical therapywith bromo-
criptine or pegvisomant and after surgery. Instead, there is some
discrepancy as regards the effects of therapy with SA on vitamin D,
which is reduced or unchanged after therapy, likely due to the different
therapeutic regimens used.
6. Concluding remarks
Themutual interplay between vitamin D and the GH/IGF-I system is
very complex. Physiologically, GH regulates renal 1 alpha-hydroxylase
activity and plasma concentrations of vitamin D and this effect may be
IGF-I mediated. On the other hand, vitamin D increases circulating
IGF-I.
Commonly, in GHD patients vitamin D levels are almost normal or
even lower than in controls, with a variable prevalence of insufﬁciency
or deﬁciency, and this condition could potentially worsen the already
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very few studies have evaluated vitamin D deﬁciency as a cardiovascu-
lar risk factor in GHD. On the other hand, the impact of GH treatment on
vitamin D levels remains controversial. Although some studies have
shown a neutral effect of GH treatment on vitamin D, GH seems to be
able to improve vitamin D levels in themajority of the studies available.
However, whether GH therapy will improve vitamin D status and
consequently also decrease cardiovascular morbidity in GHD patients
remains to be determined.
In acromegaly, vitamin D levels are commonly higher than in con-
trols or in patients with controlled disease. Both medical and surgical
treatments of acromegaly lead to a reduction in vitamin D levels in the
majority of studies, with some exceptions that proves a neutral effect
of SA treatment.
To date, the lack of large randomized and placebo-controlled studies,
the heterogeneity of the populations evaluated, the relative small study
population, the difference in the vitamin D metabolites analyzed in the
various studies and the different duration of the various treatments
make the literature still quite confusing and sometimes conﬂicting.
Nevertheless, since in the majority of the studies the conditions of GH
deﬁciency or GH excess seem to be almost always associated with
altered vitaminD levels, vitaminD should be considered a usefulmarker
of the integrity of the GH/IGF-I system and should be included among
the clinical evaluations to be performed in these conditions. However,
whether the vitamin D status in GH disorders and during their respec-
tive treatments has a signiﬁcant clinical impact, for instance inmetabolic
alterations and cardiovascular morbidity, remains to be determined.
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